Healthcare >> Analyst Interviews >> June 2, 2002
DR. MARK MONANE is Principal, Equity Research at Needham and
Company, a full-service investment bank in New York City, where
he serves as a Senior Analyst in biotechnology and
biopharmaceuticals. His coverage universe focuses on small to
mid-cap companies in the cardiovascular and cancer areas. Dr.
Monane was recently ranked number two in biotechnology in the
2002 Best on the Street Analysts Survey conducted by The Wall
Street Journal. Dr. Monane was a full-time faculty member and
researcher at Harvard Medical School from 1991 to 1996, reaching
the title of Assistant Professor of Medicine. He worked at Merck-
Medco Managed Care, LLC, as Director and then Senior Director of
Geriatrics from 1996 to 2000. Dr. Monane's research on medication
use and geriatrics has resulted in more than 50 original articles
and review publications in journals such as Journal of the
American Medical Association, Archives of Internal Medicine,
Journal of the American Geriatrics Society, Hypertension, and
Clinical Pharmacology and Therapeutics. Dr. Monane holds an AB
degree from Columbia University, an MD from New York University
School of Medicine, an MS degree from Harvard School of Public
Health, and an MBA degree from Columbia Business School. He
completed postdoctoral training in primary care internal medicine
at Montefiore Hospital, geriatric medicine at Harvard Medical
School, and geriatric clinical pharmacology at Harvard Medical
School. He is board certified in internal medicine, geriatric
medicine, clinical pharmacology, and utilization review/quality
assurance. He is currently an Adjunct Associate Clinical
Professor at Rutgers College of Pharmacy in New Jersey. He serves
on the Board of Directors for the American Federation for Aging
Research and the American Society of Consultant Pharmacists. Profile
Needham & Company?
Dr. Monane: Our coverage is focused on companies addressing large areas
of unmet needs in
